Genfit AASLD KOL Event Nov 2018 in SF

San Francisco/Los Angeles, November 11, 2018

Expert speakers to discuss elafibranor including ongoing Phase 3 trial in NASH and Phase 2a trial in PBC

 

Expert KOL Speakers to Include:

Stephen A. Harrison, MD, FACP, FAASLD, COL(ret.), USA, MC
Visiting Professor of Hepatology, Radcliffe College of Medicine, University of Oxford
Medical Director, Pinnacle Clinical Research

Dr. Jörn M. Schattenberg
Universitätsmedizin Mainz, Germany

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Genfit SA [GNFTF] US$875 MM MCap
$155m Mar 2019 US IPO; FDA BTD for Ela­fi­branor (4/19); (+) 36-mo DSMB rec for cont­in­u­a­tion of Ph 3 study in NASH; da­ta by YE [more in­for­ma­tion]